



Alameda Alliance for Health
**GROUP CARE
 FORMULARY
 UPDATE**

**Effective 08/01/2023, unless indicated
 below under Committee Actions.**

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the June 20, 2023, meeting:

Therapeutic/Monograph Class Reviews	
<ul style="list-style-type: none"> • Opioids and Opioid Combinations Class Review • Contraceptive Foams, Devices Class Review • Diuretics Class Review • Gaucher Disease Class Review • Sucraid Monograph 	<ul style="list-style-type: none"> • Ridaura Monograph • Provenge Monograph • Filspari Monograph + new MRG • Daybue Monograph + new MRG • Joenja Monograph + new MRG • Skyclarys Monograph + new MRG • Attention Deficit Hyperactivity Disorder (ADHD) Class Review

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

Generic Name & Strength/Dosage Form	Brand Name	Committee Actions
lisdexamfetamine 10 mg chewable tablet	Vyvanse 10 mg chewable tablet	Add to formulary with Prior Authorization (PA)
lisdexamfetamine 20 mg chewable tablet	Vyvanse 20 mg chewable tablet	Add to formulary with PA
lisdexamfetamine 30 mg chewable tablet	Vyvanse 30 mg chewable tablet	Add to formulary with PA
lisdexamfetamine 40 mg chewable tablet	Vyvanse 40 mg chewable tablet	Add to formulary with PA
lisdexamfetamine 50 mg chewable tablet	Vyvanse 50 mg chewable tablet	Add to formulary with PA
lisdexamfetamine 60 mg chewable tablet	Vyvanse 60 mg chewable tablet	Add to formulary with PA
methylphenidate CD 10 mg biphasic 30-70 capsule, extended release	Methylphenidate CD 10mg biphasic 30-70 capsule, extended release	Update to Quantity Limit (QL) #30/30 days
methylphenidate CD 20 mg biphasic 30-70 capsule, extended release	Methylphenidate CD 20mg biphasic 30-70 capsule, extended release	Update to QL #30/30 days
methylphenidate CD 30 mg biphasic 30-70 capsule, extended release	Methylphenidate CD 30mg biphasic 30-70 capsule, extended release	Update to QL #30/30 days

PRIOR AUTHORIZATION GUIDELINE UPDATES

Short acting opioids (part of opioid class review)	Topiramate (Topamax) sprinkles
Long-acting opioids (part of opioid class review)	Emflaza (deflazacort)
Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)	Hereditary Angioedema (HAE)
Pregabalin (Lyrica and Lyrica CR)	vigabatrin (Sabril)
Gonadotropin Releasing Hormone Antagonist Combination Products	Hepatitis C Medications
Orilissa (elagolix)	Hemlibra (emicizumab-kxwh)
Sleep Disorder Therapy	Lipotropics
Cholinesterase Inhibitors	Sedative Hypnotics
Daliresp (roflumilast)	Epidiolex (cannabidiol)
Injectable Atypical Antipsychotic Medications	

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)	
Butorphanol (part of opioid class review)	Nutritional formulas, infant formulas (STC C5F C5C)
Diuretics (part of diuretics class review)	Serotonin Receptor Agonists (Tryptans)
febuxostat (Uloric)	Rufinamide (Banzel)
Formulary, step therapy required *For drugs without specific criteria	Tiagabine (Gabitril)
Non-formulary and prior authorization required oral liquid formulations	Phosphate Binders
Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention	Movement Disorders
Lamotrigine ER	Aptiom (eslicarbazepine)
Levalbuterol (Xopenex/Xopenex HFA)	Alprazolam (Xanax)
Lidocaine Patch	Rectiv (nitroglycerin) ointment
Potassium-removing agents	Acute Migraine Treatments
Fenofibrates	Palforzia
Lupkynis	Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention
Agents for Atopic Dermatitis	

**For questions, please contact the Alliance's Pharmacy Services department at:
(510) 747-4541.**